Constipation during GLP-1 weight-loss treatment

Why constipation shows up on GLP-1 treatment

Constipation is a labeled, common gastrointestinal effect of GLP-1 medicines used for weight management. Delayed gastric emptying, lower calorie and fluid intake, and reduced gut motility can all slow stool transit. People who already have a low-fiber pattern, take constipating medicines, or drink less because of nausea are more exposed.

This page is educational, not a treatment plan. NIDDK describes constipation as fewer than three bowel movements a week for many adults, or stools that are hard, dry, or difficult to pass. A sudden change after starting or increasing a GLP-1 still belongs in a conversation with the prescribing clinician.

How often labels report constipation

In Wegovy adult weight-reduction trials, constipation occurred in 24% of treated patients versus 11% on placebo. Abdominal distension, which people often describe as bloating, occurred in 7% versus 5%. Pooled STEP analyses similarly found constipation in about one in four people on semaglutide 2.4 mg.

Zepbound tables report constipation in roughly 11% to 17% of treated patients depending on dose, versus about 5% on placebo. Those figures cannot be lined up as a contest between products. Different trials, populations, and dose ramps produce different percentages. What the labels agree on is that constipation is expected often enough to counsel patients about it.

Supportive steps clinicians may discuss

Hydration matters more when intake is already down because of nausea. Fiber from food can help some people and worsen bloating in others, especially if fluids stay low. Gentle activity, when medically appropriate, can support regularity. These are general GI principles from sources such as NIDDK, not a GLP-1-specific protocol.

A clinician may review iron, calcium, anticholinergics, and opioid pain medicines. They may also ask about bathroom access, travel, and pelvic-floor issues. Over-the-counter laxatives are not automatically safe for every person, especially with kidney disease, eating disorders, or suspected obstruction. Do not start a stimulant laxative marathon based on a search result.

Red flags that need prompt evaluation

Semaglutide labeling includes postmarketing reports of ileus, intestinal obstruction, and fecal impaction. Seek emergency care for no stool plus vomiting, severe abdominal swelling, fever, or pain that is rapidly worsening. Blood in the stool, black tarry stool, or unintentional severe weakness also needs urgent assessment.

People with a history of bowel surgery, inflammatory bowel disease, or chronic opioid use may have a narrower safety margin. New constipation after a dose increase is still worth reporting even if it seems "typical," because typical and serious can overlap at the start.

• Emergency: vomiting with no gas or stool, rigid or severely swollen abdomen, high fever, fainting.
• Same-day call: several days with no bowel movement, worsening pain, or inability to pass gas.
• Do not use enemas or high-dose laxatives if obstruction is possible until a clinician says so.

Diet, dose, and related GI symptoms

Very low intake can reduce stool volume so much that bowel movements become infrequent even without a true motility emergency. That still needs monitoring. Nausea that cuts fluid intake can worsen both constipation and kidney risk. Bloating and reflux often travel with the same delayed-emptying physiology.

If constipation is blocking further dose increases, a clinician may pause titration. That is a labeled, conservative approach. Doubling fiber overnight or skipping doses without guidance can create new problems, including rebound GI symptoms or loss of glycemic control.

What to tell a clinician

Useful details include last bowel movement, stool form, fluids, new medicines, abdominal surgeries, and whether vomiting is present. This site does not collect that information. Bring it to the visit or message the care team that prescribed the GLP-1.

Prescription weight-loss medicines require ongoing medical supervision. Completing an intake questionnaire does not guarantee a prescription, and having constipation does not automatically mean treatment must stop. The decision belongs to a licensed provider who can examine the person and review risks.

Frequently asked questions

Sources

1. [1] Wegovy (semaglutide) injection Prescribing Information. Novo Nordisk. DailyMed.
2. [2] Zepbound (tirzepatide) injection Prescribing Information. Eli Lilly. DailyMed.
3. [3] NIDDK. Constipation.
4. [4] Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Diabetes, Obesity and Metabolism. 2021.
5. [5] Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021.